Jivi
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Jivi
- Generic name
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED-AUCL
- Manufacturer
- Bayer HealthCare LLC
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- f04e5bd5-d7e2-453b-a407-2616d81a695d
- SPL ID
- 15230046-a8a7-4a1c-b279-ae307d278515
- Version
- 13
- Effective date
- 2026-03-02
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:30
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125661 | derived:openfda.application_number |
| application number | BLA125661 | openfda.application_number | |
| brand name | Jivi | openfda.brand_name | |
| generic name | ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED-AUCL | openfda.generic_name | |
| manufacturer name | Bayer HealthCare LLC | openfda.manufacturer_name | |
| ndc | package | 0026-3948-99 | openfda.package_ndc |
| ndc | package | 0026-4948-01 | openfda.package_ndc |
| ndc | package | 0026-0426-15 | openfda.package_ndc |
| ndc | package | 0026-3946-25 | openfda.package_ndc |
| ndc | package | 0026-4944-01 | openfda.package_ndc |
| ndc | package | 0026-4946-99 | openfda.package_ndc |
| ndc | package | 0026-3950-50 | openfda.package_ndc |
| ndc | package | 0026-3944-99 | openfda.package_ndc |
| ndc | package | 0026-4944-99 | openfda.package_ndc |
| ndc | package | 0026-3946-99 | openfda.package_ndc |
| ndc | package | 0026-4950-01 | openfda.package_ndc |
| ndc | package | 0026-4942-99 | openfda.package_ndc |
| ndc | package | 0026-0426-02 | openfda.package_ndc |
| ndc | package | 0026-4942-01 | openfda.package_ndc |
| ndc | package | 0026-3950-99 | openfda.package_ndc |
| ndc | package | 0026-4946-01 | openfda.package_ndc |
| ndc | package | 0026-3948-25 | openfda.package_ndc |
| ndc | package | 0026-3944-25 | openfda.package_ndc |
| ndc | package | 0026-0426-05 | openfda.package_ndc |
| ndc | package | 0026-3942-99 | openfda.package_ndc |
| ndc | package | 0026-3942-25 | openfda.package_ndc |
| ndc | package | 0026-4950-99 | openfda.package_ndc |
| ndc | package | 0026-4948-99 | openfda.package_ndc |
| ndc | product | 0026-3950 | openfda.product_ndc |
| ndc | product | 0026-3942 | openfda.product_ndc |
| ndc | product | 0026-3944 | openfda.product_ndc |
| ndc | product | 0026-3946 | openfda.product_ndc |
| ndc | product | 0026-3948 | openfda.product_ndc |
| ndc11 | package | 00026494601 | derived:openfda.package_ndc |
| ndc11 | package | 00026394299 | derived:openfda.package_ndc |
| ndc11 | package | 00026394425 | derived:openfda.package_ndc |
| ndc11 | package | 00026395050 | derived:openfda.package_ndc |
| ndc11 | package | 00026494801 | derived:openfda.package_ndc |
| ndc11 | package | 00026494401 | derived:openfda.package_ndc |
| ndc11 | package | 00026395099 | derived:openfda.package_ndc |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including severe allergic reactions, have occurred. Monitor patients for hypersensitivity symptoms. Should hypersensitivity symptoms occur, discontinue treatment with JIVI and administer appropriate treatment. Hypersensitivity reactions may also be related to antibodies against polyethylene glycol (PEG). ( 5.1 , 5.3 ) Development of Factor VIII neutralizing antibodies have occurred. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled as expected with the administered dose, then perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 , 5.3 ) Immune response to PEG, manifested as symptoms of acute hypersensitivity and/or loss of drug effect, has occurred following JIVI administration. Discontinue JIVI and switch patients to a different anti-hemophilic product. ( 5.3 , 6.1 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including severe allergic reactions, have occurred with JIVI. Monitor patients for hypersensitivity symptoms. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. If hypersensitivity reactions occur, immediately discontinue administration and initiate appropriate treatment. JIVI may contain trace amounts of mouse and hamster proteins [see Description (11) ] . Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Hypersensitivity reactions may also be related to antibodies against polyethylene glycol (PEG) [see Warnings and Precautions (5.3) ] . 5.2 Neutralizing Antibody Formation Neutralizing antibody (inhibitor) formation have occurred following administration of JIVI. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor (neutralizing antibody) [see Warnings and Precautions (5.4) ] . 5.3 Immune Response to Polyethylene Glycol (PEG) An immune response associated with IgM anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect, has occurred with JIVI administration [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) and Use in Specific Populations (8.4) ] . In the clinical trials, the IgM anti-PEG antibodies disappeared within 4-6 weeks. No immunoglobulin class switching from IgM to IgG has been observed. A low post-infusion Factor VIII level, in the absence of detectable Factor VIII inhibitors, may be due to loss of treatment effect related to high titers of anti-PEG IgM antibodies. In these cases, discontinue JIVI and switch patients to a different anti-hemophilic product. A reduced recovery of Factor VIII after start of JIVI treatment may be due to transient low titers of anti-PEG IgM antibodies. In these cases, increase the dose of JIVI until recovery of Factor VIII returns to expected levels. 5.4 Monitoring Laboratory Tests If monitoring of Factor VIII activity is performed, use a validated chromogenic assay or a selected validated one-stage clotting assay [see Dosage and Administration (2.1) ] . Laboratories intending to measure the Factor VIII activity of JIVI should check their procedures for accuracy. For JIVI, select silica-based one-stage assays may underestimate the Factor VIII activity of JIVI in plasma samples; some reagents, e.g., with kaolin-based activators, have the potential for overestimation. Therefore, the suitability of the assay must be ascertained. If a validated one-stage clotting or chromogenic assay is not available locally, then use of a reference laboratory is recommended. Monitor for development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained or if bleeding is not controlled with the expected dose of JIVI. Use Bethesda Units (BU) to report inhibitor titers.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥ 5%) were headache, fever, cough, and abdominal pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety database described in this section reflects the exposure of JIVI in four clinical studies, Study 1 (Safety and PK Study), Study 2 (PROTECT VIII), Study 3 (PROTECT Kids), and Study 4 (Alfa-PROTECT) [see Clinical Studies (14)] ). A total of 256 patients received JIVI. Patients who received JIVI for perioperative management (n=17) with treatment period of 2 to 3 weeks were excluded from pooled safety analysis but included in analysis for inhibitor development. The median exposure days (EDs) for adults, and pediatric patients ≥ 7 years of age was 92 EDs (range: 1–309) per patient. Serious adverse reactions were reported in 5 patients (<2%), all were hypersensitivity reactions. Of the 5 patients, 1 patient was ≥ 7 years of age (see Anti-PEG Antibodies ). The most common adverse reactions (incidence ≥ 5%) were headache, fever, cough, and abdominal pain (see Table 3 ). Table 3: Adverse Reactions reported in JIVI studies Pooled data from Study 1, Study 2, Study 3, and Study 4. Adverse Reactions All Patients 2-65 years of age n (%) n=256 Patients ≥7 years of age n (%) n=208 Gastrointestinal Disorders Abdominal pain 12 (5%) 10 (5%) Nausea 9 (4%) 9 (4%) Vomiting 11 (4%) 8 (4%) General Disorders and Administration Site Conditions Injection site reactions Includes injection site pruritus, injection site rash, infusion site pain and vessel puncture site pruritus 7 (3%) 6 (3%) Fever 23 (9%) 13 (6%) Immune System Disorders Hypersensitivity 9 (4%) 4 (2%) Nervous System Disorders Dizziness 3 (1%) 3 (1%) Dysgeusia 1 (0.4%) 0 Headache 32 (13%) 30 (14%) Psychiatric Disorders Insomnia 5 (2%) 5 (2%) Respiratory, Thoracic and Mediastinal Disorders Cough 22 (9%) 15 (7%) Skin and Subcutaneous Tissue Disorders Erythema Includes erythema and erythema multiforme 3 (1%) 2 (1%) Pruritus 2 (0.8%) 1 (0.5%) Rash Includes rash and rash papular 10 (4%) 5 (2%) Vascular Disorders Flushing 1 (0.4%) 1 (0.5%) Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies to JIVI in the studies described below with the incidence of anti-drug antibodies in studies with other products. Immunogenicity was evaluated during clinical trials with JIVI in 158 (including surgery patients ) previously treated adult and pediatric patients (≥ 12 years of age) severe hemophilia A (Factor VIII activity < 1%) patients with previous exposure to Factor VIII concentrates ≥ 150 EDs. There were 108 previously treated pediatric patients < 12 years of age [see Use in Specific Populations (8.4) ] . Factor VIII Inhibitors In Study 2, a Factor VIII inhibitor (1.7 BU/mL) was reported in 1 out of 144 patients [see Warning and Precautions (5.2) ] . Anti-PEG Antibodies In Study 2, immunogenicity against PEG was evaluated by anti-PEG screening and specific IgM anti-PEG ELISA assays. One patient (19 years of age) with asthma, presented at 4 exposure days (EDs) with a clinical hypersensitivity reaction after infusion of JIVI. The patient reported headache, abdominal pain, shortness of breath, and flushing, all of which resolved following his standard asthma treatment. No further medical intervention was required. The event was associated with a transient increase of IgM anti-PEG antibody titer, which was negative upon retest during follow-up within 30 days. In Study 4 (7 to <12 years of age), one pediatric patient developed high titer neutralizing anti-PEG IgM antibodies (titer 1:64) after 2 EDs associated with low post-infusion FVIII levels and loss of efficacy. Antibodies disappeared after discontinuation and patient restarted treatment with JIVI 2 months later. Three pediatric patients developed low titer and transient anti-PEG IgM antibodies (highest titer 1:4) within the first 4 EDs resulting in reduction of JIVI recovery (lowest recovery 0.8 kg/dl) in two patients and inconclusive data on recovery in one patient.
adverse reactions table
<table ID="table3" width="85%"><caption>Table 3: Adverse Reactions reported in JIVI studies<footnote ID="t3a">Pooled data from Study 1, Study 2, Study 3, and Study 4.</footnote></caption><col width="50%" align="left" valign="middle"/><col width="25%" align="center" valign="middle"/><col width="25%" align="center" valign="middle"/><thead><tr styleCode="botrule"><th styleCode="Lrule Rrule" align="center">Adverse Reactions</th><th styleCode="Rrule">All Patients 2-65 years of age n (%) n=256</th><th styleCode="Rrule">Patients ≥7 years of age n (%) n=208</th></tr></thead><tbody><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Gastrointestinal Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Abdominal pain</td><td styleCode="Rrule">12 (5%)</td><td styleCode="Rrule">10 (5%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">9 (4%)</td><td styleCode="Rrule">9 (4%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Vomiting</td><td styleCode="Rrule">11 (4%)</td><td styleCode="Rrule">8 (4%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">General Disorders and Administration Site Conditions</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Injection site reactions<footnote ID="t31">Includes injection site pruritus, injection site rash, infusion site pain and vessel puncture site pruritus</footnote></td><td styleCode="Rrule">7 (3%)</td><td styleCode="Rrule">6 (3%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Fever </td><td styleCode="Rrule">23 (9%)</td><td styleCode="Rrule">13 (6%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Immune System Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Hypersensitivity</td><td styleCode="Rrule">9 (4%)</td><td styleCode="Rrule">4 (2%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Nervous System Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Dizziness</td><td styleCode="Rrule">3 (1%)</td><td styleCode="Rrule">3 (1%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Dysgeusia </td><td styleCode="Rrule">1 (0.4%)</td><td styleCode="Rrule">0</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">32 (13%)</td><td styleCode="Rrule">30 (14%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Psychiatric Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Insomnia</td><td styleCode="Rrule">5 (2%)</td><td styleCode="Rrule">5 (2%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Respiratory, Thoracic and Mediastinal Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Cough</td><td styleCode="Rrule">22 (9%)</td><td styleCode="Rrule">15 (7%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Skin and Subcutaneous Tissue Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Erythema<footnote ID="t32">Includes erythema and erythema multiforme</footnote></td><td styleCode="Rrule">3 (1%)</td><td styleCode="Rrule">2 (1%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Pruritus </td><td styleCode="Rrule">2 (0.8%)</td><td styleCode="Rrule">1 (0.5%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Rash<footnote ID="t33">Includes rash and rash papular</footnote></td><td styleCode="Rrule">10 (4%)</td><td styleCode="Rrule">5 (2%)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule bold">Vascular Disorders</td><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr><td styleCode="Lrule Rrule">Flushing</td><td styleCode="Rrule">1 (0.4%)</td><td styleCode="Rrule">1 (0.5%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.